The introduction of the drug in Australia is sparking significant excitement within the healthcare community. This novel dual compound – acting on both GLP-1 and GIP targets – shows a potentially significant tool https://australianpeptidestore.co/retatrutide-value-bundle-starter-kit-research-peptide-australian-peptide-store/